Using Clinicopathomic Markers to Predict Neoadjuvant Chemotherapy Response in Breast Cancer

Using Clinicopathomic Markers to Predict Neoadjuvant Chemotherapy Response in Breast Cancer

This study examines retrospective clinical data on patients diagnosed with breast cancer and monitor their response to neoadjuvant chemotherapy, incidence of locoregional recurrence, distant metastasis, and disease-free survival. The hypothesis of this study is that breast cancer patients who achieve a pathological complete response (pCR) to neoadjuvant chemotherapy demonstrate distinct clinicopathomic biomarker signatures.

The specific aims of the study are to (1) to identify clinicopathomic biomarkers from pre-treatment core biopsies that are predictive of response to neoadjuvant chemotherapy, (2) determine patterns of metastasis from primary breast cancer to other distant sites, (3) determine the rates of local recurrence in breast cancer patients, and (4) to determine if there are significant radiomic, pathomic, and clinical markers for recurrence and distant metastasis.

Inclusion Criteria:

• Participants must be men and women age 18+
• Biopsy-confirmed diagnosis of invasive breast cancer; (ER+/-, PR+/-, HER2+/-)
• Any state of disease as described by AJCC v7 criteria
• Participants must have received and completed neoadjuvant chemotherapy

Exclusion Criteria:

• Participants who had other primary cancers prior to breast cancer